Population screening for hereditary and familial cancer syndromes in Valka district of Latvia by Vanags, Andrejs et al.
RESEARCH Open Access
Population screening for hereditary and familial
cancer syndromes in Valka district of Latvia
Andrejs Vanags
1*, Ilze Štrumfa
1, Andris Gardovskis
1, Viktors Borošenko
1, Arnis Āboliņš
1, Uldis Teibe
2,
Genadijs Trofimovičs
1, Edvīns Miklaševičs
1,J ānis Gardovskis
Abstract
Background: The growing possibilities of cancer prevention and treatment as well as the increasing knowledge
about hereditary cancers require proper identification of the persons at risk. The aim of this study was to test the
outcome of population screening in the scientific and practical evaluation of hereditary cancer.
Methods: Population screening for hereditary cancer was carried out retrospectively in a geographic area of Latvia.
Family cancer histories were collected from 18642 adults representing 76.6% of the population of this area.
Hereditary cancer syndromes were diagnosed clinically. Molecular testing for BRCA1 founder mutations 300 T/G,
4153delA and 5382insC was conducted in 588 persons who reported at least one case of breast or ovary cancer
among blood relatives.
Results: Clinically, 74 (0.40%; 95% confidence interval (CI): 0.32 - 0.50%) high-risk and 548 (2.94%, 95% CI: 2.71 -
3.19) moderate-risk hereditary cancer syndromes were detected covering wide cancer spectrum. All syndromes
were characterised by high cancer frequency among blood relatives ranging 8.6 - 46.2% in contrast to spouse
correlation of 2.5 - 3.6%. The mean age of cancer onset ranged 38.0 - 72.0 years in different syndromes. The BRCA1
gene mutations were identified in 10 (1.7%; 95% CI: 0.9 - 3.1%) probands. Families with established BRCA1 gene
founder mutations were identified with the frequency 1:2663 clinically screened persons.
Conclusions: Population screening is a useful practical tool for the identification of persons belonging to families
with high frequency of malignant tumours. The whole hereditary and familial cancer spectrum along with the age
structure was identified adjusting follow-up guidelines. Another benefit of the population screening is the
possibility to identify oncologically healthy persons belonging to hereditary and familial cancer families so that
appropriate surveillance can be offered. Clinical diagnostics is appropriate for population screening purposes;
molecular investigation provides additional information. In collaboration with family doctors, the screening is
technically manageable as characterised by high compliance.
Background
Development in cancer research has brought not only
expanding knowledge of cancer biology but also
improved treatment results. Even thought the number
of cancer deaths has decreased by 9% in the European
Union (EU) between 1985 and 2000, oncological dis-
eases remain an important cause of mortality and mor-
bidity [1]. The number of death due to cancer was
estimated 1.12 million in the EU in 2000 [1]. It has been
proven that hereditary background can be found for
practically all cancers [2]. In 5-10% of common cancers,
this hereditary basis represents an inherited single gene
mutation with high penetrance [3]. The cancer risk for a
healthy person can rise significantly in the presence of a
pathogenic mutation with high penetrance [4]. Further-
more, hereditary cancers arise early in life [4,5] and
naturally affect several blood relatives. Thus, hereditary
cancer determines part of the excessive risk conferred
by positive family history of concordant cancer [6-10]
making the family history a predictive factor. In order to
prevent this group of tumours, people at increased her-
editary cancer risk need to be identified earlier. How-
ever, this requires a well-planned strategy and the
essential tools for detection of people at high risk.
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basis of a cancer include analysis of family cancer his-
tory as well as molecular tests in order to reveal patho-
genic high-penetrance mutations [4,5]. The cancer
family history practically can reveal to identify cancer
family syndromes characterized by monogenic dominant
inheritance pattern with high penetrance. It can be sub-
jected to various bias like denial of serious problems,
lack of sufficient knowledge, poor compliance, inability
to express the information correctly and others. The
suggestion to check the family history data provided by
the patient is reasonable [11]. However, high accuracy
of reporting cancers, reaching 83% for first-degree rela-
tives, has been described [12,13]. The molecular genetic
testing provides objective data but can be impeded by
sensitivity restrictions and presence of new or unknown
mutation. Thus, absolute efficiency of any screening
program cannot be expected.
The best known approach in order to identify heredi-
tary cancer is careful analysis of the family cancer his-
tory and search for mutations in a patient receiving
tumour treatment [5]. Thus, the healthy family members
gain the possibility to estimate their own cancer risk and
undergo appropriate diagnostic procedures. Within the
present article, this approach is designated in short as
hospital screening. Population-based hospital screening
provides an insight into the importance of the problem
in the local population. An alternative way to detect
hereditary cancer is individual testing of persons inquir-
ing about their own cancer risk. This may lead to early
diagnostics and/or psychological support.
The third alternative for the diagnostics of hereditary
cancer is the population screening - the strategy that
targets the whole adult population within a region in
order to find out families with increased cancer risk.
Hypothetically, the benefits of such approach include
revealing of persons at risk before the tumour develop-
ment. Also, all possible hereditary cancer syndromes can
be diagnosed independently of the predominant loca-
tion. However, population screening demands time,
experienced staff and financial resources. Results on
population screening for hereditary cancer are very lim-
ited [14].
The aim of this study was to test the population
screening approach and its success in detecting heredi-
tary cancer in the northeast of Latvia.
Methods
The investigation was designed as population screening
for hereditary cancer in the Valka district - a geographi-
cal area in the northeast of Latvia (Figure 1). Family
cancer histories were collected from 18642 adult inhabi-
tants of Valka district representing 76.6% of the adult
population. The study was carried out in close
collaboration with family physicians from September
2005 until June 2007. All people were enrolled in the
study regardless of gender, ethnicity or health status.
Information on family cancer history was collected
using a questionnaire that was previously tested in hos-
pital screening [15]. The participants were asked if his/
her blood relatives have had any tumour. In case of an
affirmative answer, the participants were asked for the
localisation of the tumour and the age of patient at the
time of tumour diagnosis. If the patient has died
because of the tumour the age at death was recorded as
well. In order to verify the presence and location of
malignant tumour, information was retrieved (if avail-
able) regarding the treatment modalities (e.g. radiation
therapy and chemotherapy, extent of operation). The
interview took an estimated 45 minutes to complete.
The filled-in questionnaires were analysed by physi-
cians with experience in hereditary cancer diagnostics.
T h ea p p l i e dd i a g n o s t i cc r i t e r i ao ft h eh e r e d i t a r ya n d
familial cancer syndromes are presented in Table 1.
Within the frames of the present study, cases corre-
sponding to strict criteria [15,16] were classified into
group 1 (g1), but cases diagnosed by more relaxed cri-
teria - into group 2 (g2). The combined group was
designated g3.
Patients diagnosed with any hereditary cancer syn-
drome were invited for additional consultation in order
to confirm the diagnosis and to discuss the possibilities
of molecular diagnostics. Mutually related families were
identified in order to prevent repeated inclusion of any
affected person in further calculations.
The study was approved by the Central Commission
of Medical Ethics of Latvia. Written informed consent
was obtained from all patients.
The statistic evaluation was carried out by CIA soft-
ware [17]. The population prevalence of any hereditary
cancer syndrome was calculated as the ratio between
the number of clinically diagnosed individuals and the
whole group. The frequency of cancer among blood
relatives was estimated. Size of family was characterised
by number of blood relatives in the affected genetic line.
The course of malignant tumour was characterised by
the data about the age of tumour diagnostics and age of
tumour-related death. Using the data about the total
number of cancers reported in the kindred by all
recruited persons and the number of cancers in the
families affected by hereditary cancer syndrome, the her-
editary cancer burden was calculated for each location.
Molecular examination for the BRCA1 founder muta-
tions 300T/G, 4153delA and 5382insC as described by
Gorski et al. [18] was offered to the participants of the
study reporting at least one case of breast or ovarian
cancer in their family history. The molecular examina-
tion was provided for 588 patients.
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The population screening by clinical criteria identified
74 (0.40%; 95% confidence interval (CI): 0.32 - 0.50%)
hereditary cancer cases of group 1. Hereditary gastric
cancer (HGC) was the most common syndrome, fol-
lowed by familial lung cancer (FLC) and hereditary non-
polyposis colorectal cancer (HNPCC) syndromes (Figure
2). In addition, 548 (2.94%, 95% CI: 2.71 - 3.19%) pro-
bands reported family history corresponding to group 2
criteria (Table 2). Here, breast and ovarian cancers were
dominating locations, followed by lung cancer (Figure
3). Renal and testicular cancers were among the loca-
tions not reported by the applied criteria. The popula-
tion prevalence of each hereditary and familial cancer
syndrome ranged 0.005 - 0.11% in group 1 and 0.05 -
1.18% in group 2 (Table 2).
The identified pedigrees of hereditary and familial
cancer syndromes were characterised by generally high
frequency of malignant tumours among the blood rela-
tives as shown in Table 2. The highest cancer frequency
was recorded in the following groups: HEC/g1 (41.5%,
95% CI: 27.8 - 56.6%), the whole hereditary and familial
endometrial cancer group (41.0%, 95% CI: 36.1 - 46.2%),
HNPPC/g1 (30.1%, 95% CI: 23.3 - 38.0%), FLC/g1
(25.5%, 95% CI: 19.3 - 32.8%) and HGC/g1 (25.2%, 95%
CI: 20.6 - 30.4%). In contrast, the spouse correlation was
as low as 2.5% (95% CI: 0.7 - 8.6%) in FLC/g3 families
and 3.6% (95% CI: 1.2 - 10.1%) in HGC/g3 families.
Comparison of cancer frequency between groups 1
and 2 was carried out for each location. For some loca-
tions statistically significant difference was found con-
firming the patient stratification. Thus, in case of
HNPCC and HGC the cancer frequency was 30.1% (95%
CI: 23.3 - 38.0%) vs. 15.5% (95% CI: 11.6 - 20.3%) and
25.2% (95% CI: 20.6 - 30.4%) vs. 16.0% (95% CI: 13.8 -
18.5%), respectively. The importance of both g1 and g2
proper identification was demonstrated by following
data. Close frequencies of colorectal cancer was
observed in HNPCC/g1, HNPCC/g2 and FCC/g2,
namely 15.8% (95% CI: 10.7 - 22.5%), 10.6% (95% CI: 7.4
Figure 1 Geographic localisation of Latvia (encircled) with Valka district (dot).
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Hereditary syndrome Diagnostic criteria
Hereditary non-polyposis colorectal cancer,
group 1
a (HNPCC/g1)
Amsterdam II criteria [15]
HNPCC, group 2 (HNPCC/g2) At least 2 first degree relatives with HNPCC associated cancer (colorectal, endometrial, small bowel,
ureteric, renal pelvis) and at least one cancer diagnosed before age 50
Familial colorectal cancer, group 2 (FCC/g2) Colorectal cancer in at least two first or second degree relatives. HNPCC and familial adenomatous
polyposis should be excluded
Hereditary breast cancer, group 1 (HBC/g1) At least 3 breast cancer patients in family and one of those patients is first degree relative to other
two or second degree relative through male
Hereditary breast cancer, variety 1, group 2
(HBC1/g2)
At least one of the following criteria:
1) Breast cancer diagnosed under the age of 40;
2) Medullary or atypical medullary breast cancer;
3) Male breast cancer;
4) Bilateral breast cancer, one of them diagnosed under the age of 50.
Hereditary breast cancer, variety 2, group 2
(HBC2/g2)
Two breast cancer cases among first degree relatives (or second degree through male)
Hereditary ovarian cancer, group 1 (HOC/g1) At least 3 ovarian cancer cases in family and one of those patients is first degree relative to other
two or second degree relative through male
Hereditary ovarian cancer, group 2 (HOC/g2) Two ovarian cancer cases among first degree relatives
Hereditary breast-ovarian cancer, group 1
(HBOC/g1)
At least 3 breast or ovarian cancer patients in family at any age and one of those patients is first
degree relative to other two or second degree relative through male
Hereditary breast-ovarian cancer, variety 1,
group 2 (HBOC1/g2)
Breast and ovarian cancer in the same individual at any age
Hereditary breast/ovarian cancer, variety 2,
group 2 (HBOC2/g2)
One breast cancer diagnosed under the age of 50 and one ovarian cancer diagnosed at any age
among first degree relatives or second degree relatives through male
Hereditary endometrial cancer, group 1 (HEC/
g1)
At least 3 first degree relatives with endometrial cancer and at least one of them diagnosed before
age of 50
Hereditary endometrial cancer, group 2 (HEC/
g2)
Two first degree relatives with endometrial cancer and at least one of them diagnosed before age of
50
Familial endometrial cancer, group 1 (FEC/g1) At least 3 first degree relatives with endometrial cancer. HEC/g1 should be excluded
Familial endometrial cancer, variety 1, group
2 (FEC1/g2)
At least 2 first degree relatives with endometrial cancer. HEC/g2 should be excluded
Familial endometrial cancer, variety 2, group
2 (FEC2/g2)
At least 2 second degree relatives with endometrial cancer
Familial lung cancer, group 1 (FLC/g1) At least 3 first degree relatives with lung cancer
Familial lung cancer, group 2 (FLC/g2) Two first degree relatives with lung cancer
Hereditary gastric cancer, group 1 (HGC/g1) At least 3 first degree relatives with gastric cancer
Hereditary gastric cancer, group 2 (HGC/g2) Two first degree relatives with gastric cancer
Hereditary prostate cancer, group 1 (HPC/g1) At least 3 blood relatives with prostate cancer at any age or 2 blood relatives with prostate cancer
diagnosed before age of 55 in both of them
Hereditary prostate cancer, group 2 (HPC/g2) Two blood relatives with prostate cancer at any age or a case of prostate cancer diagnosed before
age of 55
Familial brain tumour, group 1 (FBT/g1) At least 3 first degree relatives with brain tumour
Familial brain tumour, group 2 (FBT/g2) Two first degree relatives with brain tumour
Familial malignant haematological tumour,
group 1 (FHemT/g1)
At least 3 first degree relatives with malignant haematological tumour
Familial malignant haematological tumour,
group 2 (FHemT/g2)
Two first degree relatives with malignant haematological tumour
Familial pancreatic tumour, group 1 (FPan/
g1)
At least 2 first degree relatives with pancreatic tumour or melanoma
Familial urinary bladder cancer, group 1
(FBlaC/g1)
At least 3 first degree relatives with urinary bladder cancer
Familial urinary bladder cancer, group 2
(FBlaC/g2)
Two first degree relatives with urinary bladder cancer
Other familial cancer syndromes At least 3 first degree relatives with concordant cancer
agroups 1 and 2 were defined for the use solely within the presented study.
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individual syndromes of hereditary or familial endome-
trial cancer showed close frequencies of endometrial
cancer although significant difference was observed
among combined g1 and g2 endometrial cancer syn-
dromes (Table 2).
The health status of the probands was analysed as one
of the major aspects characterising both the population
screening approach, and particular hereditary cancer
syndromes (Table 2). Low frequency of the affected pro-
bands was recorded in FLC (0%, 95% CI: 0 - 3.5%), in
FBT (0%, 95% CI: 0 - 16.8%), in HGC (1.1%, 95% CI: 0.2
- 5.7%) as well in FBlaC (0%, 95% CI: 0 - 25.9%). The
highest frequency of affected probands was observed in
HPC (22.2%, 95% CI: 16.5 - 29.0%) and in the whole
group of hereditary and familial endometrial cancer
(14.3%, 95% CI: 7.4 - 25.7%).
There was statistically significant difference between
the size of family diagnosed with a group 1 or 2 heredi-
tary cancer syndrome and families with non-diagnostic
findings (Table 3).
The mean age of cancer diagnostics and cancer-
related death is presented in Table 4. The lowest mean
age of cancer diagnostics was found in HBC1/g2 (38.0
years, 95% CI: 36.2 - 39.7 years), at least partially due to
the selection criteria. The mean age was low in FBT
(43.9 years, 95% CI: 35.0 - 52.8 years) and in FHemT
(47.5 years, 95% CI: 38.9 - 56.1 years), at least partially
due to the cancer occurrence in childhood. The mean
age was below 50 years in few other groups: HBC/g1
(47.5 years, 95% CI: 37.1 - 57.8 years), in HEC/g2 (48.5
years, 95% CI: 44.4 - 52.6 years), in HBOC1/g2 (48.8
years, 95% CI: 44.2 - 53.3 years), in HOC/g1 (49.7 years,
95% CI: 4.0 - 95.4 years) and in HNPCC/g1-related
endometrial cancer (48.4 years, 95% CI: 43.4 - 53.4
years). FBlaC/g3 was characterised by high mean age of
tumour diagnostics (70.7 years, 95% CI: 66.7 - 74.7
years, respectively) as well as HPC/g1 (72.0 years, 95%
CI: 67.0 - 76.9 years) and FCC/g2 (72.0 years, 95% CI:
67.3 - 76.7 years). The proportion of cases occurring
before the age of 50 was statistically significantly higher
in the hereditary group than in whole population for
colorectal, endometrial, breast, lung cancer and haema-
tological tumours (Table 5).
The hereditary cancer burden by location is shown in
Table 6. All the most frequent cancer locations are
characterized by hereditary cancer burden exceeding
10% at group 3 level. The hereditary cancer burden
averaged 2.4 - 4.7% for frequently encountered tumours
as colorectal, endometrial, ovarian, lung and gastric can-
cer in group 1.
During the population screening in Valka district 10
BRCA1 gene mutations in 7 families were found, repre-
senting 1.7% (95% CI: 0.9 - 3.1%) of the molecularly
Figure 2 The reciprocal proportions of hereditary cancer syndromes within group 1. Abbreviations of the syndromes are followed by
absolute number of identified probands with the corresponding diagnosis and the proportion within the group 1. HCRC is used to comprise
both HNPCC and FCC.
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screened Valka population. None of the mutation car-
riers was diagnosed by clinical criteria of group 1
(Table 7).
The frequency of breast cancer in BRCA1 founder
mutation carriers was 20%; 95% CI = 5.7 - 51.0] but in
tested mutation-negative probands - 10.6% (95% CI =
8.3 - 13.3%). The corresponding incidence rates were
657.9 (95% CI = 79.7 - 2376.5) and 221.8 (95% CI =
169.7 - 284.9) per 100 thousands. There were no ovarian
cancer cases in BRCA1 mutation carriers, corresponding
to the frequency 0% (95% CI = 0 - 27.8%) and incidence
rate 0 (95% CI = 0 - 1213) per 100 thousands. In
BRCA1-mutation negative persons the frequency of
ovarian cancer was 1.2% (95% CI = 0.6 - 2.5%) and inci-
dence rate - 25.4 (95% CI = 10.2 - 52.4) per 100
thousands.
Discussion
For many cancer locations, epidemiologic data suggest
that positive family history is a risk factor [6-10]. The
identification of the responsible genes and mutations is
a major achievement of medical science providing the
final evidence of the hereditary nature of a subgroup of
cancers as well as practical tool for risk evaluation.
Table 2 Characteristics of hereditary cancer syndromes
by population prevalence, proband’s health status and
frequency of index cancers among blood relatives
Diagnosis Population
prevalence
Affected
probands
Cancer frequency
Value,
%
95% CI,% Fr,
%
95% CI,% Value,
%
95% CI,%
HNPCC/
g1
0.06 0.03 - 0.10 18.2 5.1 - 47.7 30.1 23.3 - 38.0
15.8
CRC 10.7 -
22.5
CRC
22.4
EF 14.8 -
32.3
EF
HNPCC/
g2
0.11 0.07 - 0.17 5 0.9 - 23.6 15.5 11.6 - 20.3
10.6
CRC 7.4 -
14.8
CRC
9.6
EF 5.7 - 15.8
EF
HNPCC/
g3
0.17 0.12 - 0.24 9.7 3.3 - 24.9 19.3 16.5 - 22.5
12.4
CRC 9.6 -
15.9
CRC
14.5
EF 10.5 -
19.8
EF
FCC/g2 0.11 0.07 - 0.17 5 0.9 - 23.6 17.0 12.8 - 22.3
HB+OC/
g1
0.03 0.01 - 0.06 20 3.6 - 62.4 24.6
F 15.5 - 36.7
F
HBC1/g2 0.63 0.52 - 0.75 4.3 1.8 - 9.6 8.6 7.2 - 10.2
16.3
F 13.8 -
19.1
F
HBC2/g2 0.34 0.27 - 0.44 18.8 11.1 - 30.0 31.8
F 27.5 -
36.4
F
HBOC1/g2 0.03 0.02 - 0.07 0 0 - 39.0 19.3
F 9.2 - 36.3
F
HBOC2/g2 0.16 0.11 - 0.22 20.7 9.8 - 38.4 30.8
F 25.0 -
37.3
F
HOC/g2 0.008 0.001 -
0.06
0 0 - 49.0 36.4
F 19.7 -
57.0
F
HB+OC/
g2
1.18 1.04 - 1.35 10.5 7.1 - 15.2 12.6
F 11.4 - 13.9
F
23.6
F 21.4 -
25.9
F
HEC/g1 0.03 0.01 - 0.06 0 0 - 43.3 41.5
F 27.8 -
56.6
F
HEC/g2 0.14 0.10 - 0.20 15.4 6.2 - 33.5 32.2
F 25.7 - 39.4
F
FEC/g1 0.01 0.003 -
0.04
0 0 - 65.8 46.2
F 23.2 - 70.9
F
FEC1/g2 0.13 0.09 - 0.19 12.5 4.3 - 31.0 28.7
F 22.4 - 36.0
F
FEC2/g2 0.05 0.03 - 0.09 11.1 2.0 - 43.5 32.4
F 22.4 - 44.2
F
H+FEC/g1 0.04 0.02 - 0.08 0 0 - 35.4 42.6
F 36.3 - 55.8
F
H+FEC/g2 0.32 0.25 - 0.41 13.6 7.0 - 24.5 30.8
F 26.5 - 35.4
F
H+FEC g3 0.35 0.28 - 0.45 14.3 7.4 - 25.7 41.0
F 36.1 - 46.2
F
HGC/g1 0.11 0.07 - 0.17 4.8 0.8 - 22.7 25.2 20.6 - 30.4
HGC/g2 0.40 0.32 - 0.50 0 0 - 4.9 16.0 13.8 - 18.5
HGC/g3 0.51 0.42 - 0.62 1.1 0.2 - 5.7 18.2 16.2 - 20.5
Table 2 Characteristics of hereditary cancer syndromes
by population prevalence, proband’s health status and
frequency of index cancers among blood relatives
(Continued)
FLC/g1 0.07 0.04 - 0.12 0 0 - 22.8 25.5 19.3 - 32.8
FLC/g2 0.50 0.41 - 0.61 0 0 - 4.0 17.2 15.0 - 19.7
FLC/g3 0.57 0.47 - 0.69 0 0 - 3.5 18.3 16.2 - 20.7
HPC/g1 0.005 0.001 -
0.03
100 20.7 - 100 21.4
M 7.6 - 47.6
M
HPC/g2 0.11 0.07 - 0.17 19.0 7.7 - 40.0 22.2
M 16.4 -
29.4
M
HPC/g3 0.12 0.08 - 0.18 22.7 10.1 - 43.4 22.2 16.5 - 29.0
FPanC/g1 0.05 0.03 - 0.10 10 1.8 - 40.4 14.7 9.1 - 22.9
FBlaC/g1 0.01 0.003 -
0.04
0 0 - 65.8 31.6 15.4 - 54.0
FBlaC/g2 0.05 0.03 - 0.09 0 0 - 29.9 20.0 11.8 - 31.8
FBlaC/g3 0.06 0.03 - 0.11 0 0 - 25.9 22.8 14.9 - 33.2
FHemT/g1 0.005 0.001 -
0.03
0 0 - 79.3 30.8 12.7 - 57.6
FHemT/g2 0.09 0.05 - 0.14 6.3 1.1 - 28.3 15.4 11.2 - 20.9
FHemT/g3 0.09 0.06 - 0.15 5.9 1.0 - 27.0 16.3 12.1 - 21.2
FBT/g1 0.02 0.005 -
0.05
0 0 - 56.2 32.3 18.6 - 49.9
FBT/g2 0.09 0.05 - 0.14 0 0 - 19.4 14.4 10.4 - 19.5
FBT/g3 0.10 0.07 - 0.16 0 0 - 16.8 16.5 12.5 - 21.5
CRC colorectal cancer;
EF endometrial cancer in female;
F in female;
M in male
CI, confidence interval; Fr, frequency; HB+OC, combined group of hereditary
breast and/or ovarian cancer; H+FEC, combined group of hereditary and
familial endometrial cancer.
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genetic heterogeneity, involving unknown mutations and
genes, as well as multifactorial inheritance [5]. Techno-
logical factors can influence the testing as even sensitive
techniques have less than 90% sensitivity for all possible
mutations and large deletions can be missed by sequen-
cing [11]. For some tumours, e.g. lung cancer [19], only
the susceptibility loci are identified. Despite the lack of
comprehensive molecular proof the hypothesis of risk
group identification by family history [5] seems reason-
able and desirable for cancer eradication.
Against this background the population screening for
hereditary cancer is a rather novel approach. It is
embarrassed by difficulties including variability of
diagnostic criteria [16] and lack of comprehensive mole-
cular genetic testing.
To our best knowledge, only one study on population
screening for hereditary cancer [14] is published as yet.
In this study carried out in the West Pomeranian region
of Poland family cancer history of 1.2 million individuals
was evaluated by questionnaire. So results presented in
this paper are of great interest. However, further studies
with extended statistical analysis are desirable. Expand-
ing the design of population screening, originally pro-
vided by Gronwald et al. [14], we have analysed the age
of cancer development as well as cancer frequency
among blood relatives, health status of probands and
hereditary cancer burden by location. The obtained data
have both practical significance in cancer prevention
and scientific novelty presenting the full spectrum of
hereditary cancers.
The performed population screening yielded reason-
able number of hereditary and familial cancer syndrome
diagnoses. As comprehensive mutation analysis is not
possible at the present the high frequency of index can-
cer among blood relatives in the identified groups can
be considered as a risk indicator and also as an evidence
o ft h ee x p e d i e n c eo ft h ea p p l i e dc r i t e r i a .W et e s t e d2
sets of criteria - strict and more relaxed one paralleling
the published approach [5]. Both sets identified families
Figure 3 The reciprocal proportions of hereditary cancer syndromes within group 2. Abbreviations of the syndromes are followed by
absolute number of identified probands with the corresponding diagnosis and the proportion within the group 2. HCRC is used to comprise
both HNPCC and FCC.
Table 3 The reported family size in hereditary or familial
cancer syndromes and other status of family cancer
history
Group The number of blood relatives
Interval Mean SD 95% CIM
g1 7 - 29 13.6 4.9 12.2 - 15.0
g2 3 - 47 12.2 4.8 11.7 - 12.7
Not diagnostic 4 - 25 9.5 3.8 8.9 - 10.1
SD, standard deviation; CIM, confidence interval for the mean.
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these criteria to identify persons for primary and sec-
ondary prevention and surveillance. However, further
studies will probably limit the follow-up group as our
study had a major drawback: due to historical reasons,
older medical documentation was not available necessi-
tating elaborating simple questionnaire in accordance
with the reported acceptable rate of accurate reporting
cancer in relatives [12].
The clustering of cancer can occur due to chance. The
familial risk can also be attributed to hereditary muta-
tions or shared environment and lifestyle factors includ-
ing heritability of lifestyle. In our study, the spouse
correlation in such locations as lung or gastric cancer
with significant role of known environmental risk factors
[7,20] was lower than the frequency of cancer among
blood relatives pointing towards the presence of genetic
background.
Table 4 The age of hereditary cancer diagnostics and cancer-related death by population screening data
Syndrome Age of diagnosis Age of death
Interval (years) Mean (95% CIM) Interval (years) Mean (95% CIM)
HBC/g1 40 - 55 47.5 (37.1 - 57.8) 50 - 60 54.7 (50.0 - 59.4)
HBC1/g2 20 - 70 38.0 (36.2 - 39.7) 26 - 78 44.7 (41.7 - 47.7)
HBC2/g2 25 - 82 51.8 (48.9 - 54.6) 25 - 66 60.9 (56.7 - 65.1)
HBOC/g1 34 - 82 61.0 (46.9 - 75.0) 58 - 85 71.4 (54.9 - 87.9)
HBOC1/g2 40 - 60 48.8 (44.2 - 53.3) 47 - 69 54.3 (42.3 - 66.3)
HBOC2/g2 18 - 86 56.6 (51.8 - 61.4) 23 - 87 66.1 (61.2 - 71.0)
HOC/g1 34 - 70 49.7 (4.0 - 95.4) 72 72
HOC/g2 45 - 70 54.2 (46.4 - 61.9) 47 - 72 57.2 (50.1 - 64.3)
HNPCC/g1 30 - 77 54.2 (50.2 - 58.2) 28 - 89 61.7 (54.2 - 69.2)
CRC 36 - 77 59.3 (53.8 - 64.8) 28 - 89 61.5 (52.9 - 70.0)
E 30 - 65 48.4 (43.4 - 53.4) 37 - 72 NA
HNPCC/g2 27 - 82 53.7 (49.1 - 58.3) 28 - 88 55.5 (49.5 - 61.5)
CRC 28 - 82 55.2 (49.1 - 61.3) 32 - 88 56.7 (49.9 - 63.5)
E 27 - 72 50.5 (43.0 - 58.0) 28 - 73 51.2 (33.1 - 69.3)
FCC/g2 41 - 89 72.0 (67.3 - 76.7) 52 - 90 76.3 (73.1 - 79.5)
HEC/g1 40 - 75 52.1 (47.2 - 57.0) 44 - 76 57.7 (49.6 - 65.8)
HEC/g2 30 - 81 48.5 (44.4 - 52.6) 35 - 87 58.7 (53.6 - 63.8)
FEC/g1 52 - 90 66.3 (63.0 - 69.6) 54 - 91 71.7 (68.6 - 74.8)
FEC1/g2 60 - 78 67.0 (53.1 - 80.9) 65 - 86 79.2 (69.0 - 84.4)
FEC2/g2 26 - 82 57.6 (49.9 - 65.3) 26 - 83 63.3 (54.7 - 71.9)
FLC/g1 35 - 78 56.0 (53.0 - 59.0) 36 - 79 57.1 (54.1 - 60.1)
FLC/g2 18 - 90 58.5 (56.1 - 60.9) 13 - 90 61.2 (59.1 - 63.3)
FLC/g3 18 - 90 57.9 (55.9 - 59.9) 13 - 90 61.2 (58.5 - 62.1)
HGC/g1 30 - 83 56.9 (53.4 - 66.3) 30 - 90 58.3 (55.3 - 61.3)
HGC/g2 34 - 95 62.5 (60.1 - 64.8) 37 - 96 65.6 (63.4 - 67.6)
HPC/g1 70 - 74 72.0 (67.0 - 76.9) 72 NA
HPC/g2 35 - 75 56.8 (52.8 - 60.8) 37 - 80 59.7 (54.6 - 64.8)
HPC/g3 35 - 75 57.7 (53.3 - 62.1) 37 - 80 60.7 (55.0 - 66.4)
FBlaC/g1 60 - 75 67.5 (53.7 - 81.3) 65 - 75 70.3 (65.6 - 75.0)
FBlaC/g2 61 - 87 71.8 (67.3 - 76.3) 72 - 92 79.3 (74.1 - 84.5)
FBlaC/g3 60 - 87 70.7 (66.7 - 74.7) 65 - 92 75.7 (71.6 - 79.8)
FHemT/g1 45 - 61 50.7 (28.4 - 73.0) 46 - 50 48.0 (22.6 - 73.4)
FHemT/g2 3 - 88 47.1 (37.5 - 56.7) 4 - 90 49.9 (39.7 - 60.1)
FHemT/g3 3 - 88 47.5 (38.9 - 56.1) 4 - 86 49.8 (40.5 - 59.1)
FPanC/g1 51 - 72 61.6 (57.3 - 65.9) 51 - 83 63.4 (58.2 - 68.6)
FBT/g1 59 - 60 59.7 (58.3 - 61.1) 50 - 65 59.7 (54.3 - 65.1)
FBT/g2 2 - 77 41.8 (32.0 - 51.6) 2 - 75 45.2 (35.9 - 54.5)
FBT/g3 2 - 77 43.9 (35.0 - 52.8) 2 - 77 47.8 (39.7 - 55.9)
CIM, confidence interval for the mean; CRC, colorectal cancer; E, endometrial cancer; NA, not applicable.
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Page 8 of 11The majority of the identified probands were healthy
people. This approach using simple questionnaire helps
to identify healthy persons belonging to families with a
high frequency of particular malignant tumours.
Surveillance should be advised for most of these people
as follow-up is available for several common syndromes,
and early diagnostics may have general benefit in reduc-
tion of mortality. Furthermore, during population cancer
screening in Valka district the mean age of familial can-
cer onset in different locations was determined facilitat-
ing planning of prophylactic health check-up. The
crucial value of population screening relies not only on
surveillance but also on prevention and adjusted treat-
ment options in the case of established hereditary can-
cer [21,22]. Prophylactic surgical intervention is possible
only after objective verification of the diagnosis [23].
The full spectrum of hereditary cancers was revealed
including breast, lung, stomach, large bowel and endo-
metrium as main primary locations. The high propor-
tion of breast, colorectal and gastric cancer among the
familial cancers is similar to the findings in Poland [14].
Notably, no kindreds with renal cancer aggregation were
identified by the applied criteria. However, these criteria
reflect the dominant mode of transmission. A recessive
mode of inheritance for renal cancer has been suggested
[9] and in this case our criteria based on dominant
mode are not applicable.
The full data set of hereditary cancer burden by loca-
tion in the same group was obtained by population
screening. The burden of hereditary colorectal cancer
corresponds to the wide published spectrum of 1 - 13%
but is lower than average estimates 5 - 6% [24]. As
expected, it exceeds the described proportion of families
corresponding to Amsterdam criteria [25] although
similar proportions have also been reported [26]. The
burden of hereditary gastric cancer is higher than esti-
mated by Cisco et al. [27]. Only small fraction of breast
cancers corresponds to the strict criteria in contrast to
frequent occurrence of relaxed (g2) criteria and heredi-
tary ovarian cancer. As the occurrence of g1 hereditary
breast cancer is rare and results from clinical screening
and molecular testing do not mutually overlap, the real
burden of hereditary breast-ovarian cancer is much
higher than identified by g1 criteria. In contrast, the
burden of familial lung cancer in our study was 2.4%
that is higher than in Japan and USA (0.2 - 0.4%) by the
same criteria [19,28]. Notably, the genetically deter-
mined predisposition to lung cancer can interact with
smoking [19,29] therefore these factors cannot be con-
sidered mutually exclusive. The burden of familial pan-
creatic cancer in our study was 6.3% that is in line with
other published results [see for reference [30]].
The population screening for disease-causing muta-
tions [31,32] becomes rational if it corresponds to cer-
tain criteria. The disease must be common and serious,
with high penetrance and manageable number of predo-
minant mutations. The test must be cheap, acceptable
to whole population and an effective surveillance must
Table 5 The proportion of early-onset cancer cases by
location in the hereditary group in comparison with the
whole studied Valka population
Location Hereditary cancers Valka population
N Prop. (95%
CI)
N Prop. (95%
CI)
p<
0.05
1
Colorectal 19/92 20.6 (13.6-
30.0)
43/777 5.8 (4.3-7.7) Yes
Endometrial 51/181 28.2 (22.1-
35.1)
158/
1094
15.1(13.1-
17.5)
Yes
Breast 170/
310
54.8 (49.3-
60.3)
279/
1364
21.8(19.7-
24.2)
Yes
Ovarian 16/51 31.4 (20.3-
45.0)
39/156 27.1 (20.5-
34.9)
No
Lung 35/232 15.0 (11.1-
20.3)
147/
1795
8.3 (7.1-9.6) Yes
Stomach 20/225 8.9 (5.8-13.3) 162/
1615
10.2 (8.8-
11.8)
No
Pancreas 0/21 0 (0-15.5) 19/302 6.3 (4.1-9.6) No
Prostate 4/37 10.8 (4.3-
24.7)
12/499 2.6 (1.5-4.4) No
Haematologic 13/37 35.1 (21.8-
51.2)
115/
687
16.9 (14.3-
19.9)
Yes
Urinary
bladder
0/24 0 (0-13.8) 11/249 4.6 (2.6-8.1) No
Brain 10/43 23.3 (13.1-
37.3)
14/96 14.9 (9.1-
23.5)
No
1Difference statistically significant at p < 0.05
N, number of early-onset cases/whole number of reported cases; Prop.,
proportion.
Table 6 Hereditary cancer burden by location
Origin of the
tumour
Hereditary cases,
group 3
Hereditary cases,
group 1
Fraction,
%
95% CI,% Fraction,
%
95% CI,
%
Colorectal 11.8 9.8 - 14.3 3.0 2.0 - 4.4
Endometrial 16.5 14.5 -
18.9
3.8 2.9 - 5.1
Breast 25.0 22.7 -
27.4
0.8 0.4 - 1.4
Ovarian 35.4 28.1 -
43.5
3.5 1.5 - 7.9
Lung 12.9 11.5 -
14.6
2.4 1.8 - 3.2
Stomach 13.8 12.2 -
15.6
4.7 3.8 - 5.9
Pancreas 6.3 4.1 - 9.6 6.3 4.1 - 9.6
Melanoma 20.0 8.1 - 41.6 10.0 2.8 - 30.1
Prostate 7.4 5.4 - 10.1 0.6 0.2 - 1.8
Haematologic 5.4 3.9 - 7.3 0.6 0.2 - 1.5
Urinary bladder 9.6 6.6 - 13.9 2.4 1.1 - 5.2
Vanags et al. Hereditary Cancer in Clinical Practice 2010, 8:8
http://www.hccpjournal.com/content/8/1/8
Page 9 of 11be feasible [31]. It was shown earlier that BRCA1 gene
founder mutations 4153delA and 5382insC are common
in Latvia [15,33].
In order to fulfil the assumption of the economic effi-
cacy of the screening test, only founder mutations in the
BRCA1 gene were searched for and testing was offered
only to the persons who reported at least one case of
breast and/or ovarian cancer in the family. Part of the
BRCA1 mutations may be missed by this approach.
However, in this way we found 10 mutation carriers in
7 families that correspond to 2663 clinically screened
persons per one mutation-bearing family. This value is
comparable with data obtained by Gronwald et al. [14]
who reported 438 mutation-bearing families correspond-
ing to 2873 clinically screened persons per one muta-
tion-bearing family.
The number of BRCA1 mutations exceeds the one of
probands diagnosed by clinical criteria for hereditary
breast-ovarian cancer, group 1. None of the BRCA1
mutation carriers was identified by group 1 clinical diag-
nostic criteria and 8 of them reported only isolated cases
of index cancer among blood relatives. Thus, clinical cri-
teria revealed less than half of high-risk persons. The
finding of the BRCA1 mutations in individuals with no
significant family history may be explained by paternal
inheritance, lack of knowledge of the family cancer his-
tory or small family size. In this study, the inheritance
through male was ascertained by criteria. The signifi-
cance of the family size was demonstrated by higher
number of blood relatives in group 1 and 2 in compari-
son to non-diagnostic family histories.
The BRCA mutations are known to be associated with
high lifetime breast cancer risk [23]. Although the
patient group was already selected for BRCA1 testing by
positive family history of breast cancer that might
include also presence of breast cancer in the individual
there is a trend towards higher breast cancer frequency
and incidence rate in mutation carriers. The difference
does not gain statistical significance due to small sample
size and specific group design.
Clinical population screening by relaxed criteria can
be highly recommended as it yields high number of per-
sons to whom further surveillance should be advised.
This is a practical advantage of population screening for
hereditary cancer.
Conclusions
1. Population screening is a useful practical tool for
the identification of persons belonging to families
with high frequency of malignant tumours. Another
benefit of the population screening is the possibility
to identify oncologically healthy persons belonging
to hereditary and familial cancer families so that
appropriate surveillance can be offered.
2. The population screening based on clinical criteria
reveals the full spectrum of hereditary cancers. Her-
editary gastric cancer, familial lung cancer, heredi-
tary non-polyposis colorectal cancer and hereditary
breast and/or ovarian cancer were among the most
common hereditary cancer syndromes.
3. Population screening discloses the age structure of
hereditary cancer in the population helping to adjust
the surveillance programs.
4. In collaboration with family doctors, the screening
is technically manageable as characterised by high
compliance (76.6%).
5. Molecular examination is an important tool in the
evaluation of individual risk. It should be applied to
all persons with at least single breast and/or ovarian
cancer case in family if testing for founder mutations
is available.
6. Families with established BRCA1 gene founder
mutations were identified with the frequency 1:2663
clinically screened persons.
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